| 新型冠状病毒肺炎治疗联合用药潜在药品不良反应分析 |
| |
| 引用本文： | 杨勇,张灵,姚敏,沈浩,路文柯,何元媛,张子雨,萨日娜,孟敏.新型冠状病毒肺炎治疗联合用药潜在药品不良反应分析[J].中国药业,2020(7):22-26. |
| |
| 作者姓名： | 杨勇 张灵 姚敏 沈浩 路文柯 何元媛 张子雨 萨日娜 孟敏 |
| |
| 作者单位： | 四川省医学科学院·四川省人民医院药学部;四川省资阳市人民医院药学部;电子科技大学医学院;北京中医药大学;甘肃省人民医院药剂科 |
| |
| 基金项目： | 国家临床重点专科建设项目[30305030698];四川省省级公益性科研院所基本科研业务专项课题[2018YSKY0017];四川省人民医院院级科研基金临床研究及转化项目[2018LY09]。 |
| |
| 摘 要： | 目的探讨联合用药治疗新型冠状病毒肺炎的潜在药品不良反应,保障用药安全。方法根据药品说明书、丁香园用药助手、《新编药物学》,以及中国知网、维普数据库、万方数据库、Micromedex及UpToDate临床顾问等药品信息,结合临床药学实践经验,分析联合用药可能出现的相互作用和不良反应,以及药学监护要点。结果武汉方舱医院和抗疫定点医院常用36个药品品种存在较多相互作用,有发生潜在不良反应的可能性。中药注射剂和中药汤剂存在用药禁忌及注意事项,且中西药联用需加强药学监护。结论联合用药治疗新型冠状病毒肺炎存在较多潜在药品不良反应,中西药联合治疗需整体评估药物相互作用,个体化调整治疗方案,并加强药学监护。
|
| 关 键 词： | 新型冠状病毒肺炎 合理用药 药品不良反应 药物相互作用 药学监护 |
Potential Adverse Drug Reactions in the Patients with Coronavirus Disease 2019 Treated with Combined Medication |
| |
| YANG Yong,ZHANG Ling,YAO Min,SHEN Hao,LU Wenke,HE Yuanyuan,ZHANG Ziyu,SA Rina,MENG Min.Potential Adverse Drug Reactions in the Patients with Coronavirus Disease 2019 Treated with Combined Medication[J].China Pharmaceuticals,2020(7):22-26. |
| |
| Authors: | YANG Yong ZHANG Ling YAO Min SHEN Hao LU Wenke HE Yuanyuan ZHANG Ziyu SA Rina MENG Min |
| |
| Institution: | (Department of Pharmacy,Sichuan Academy of Medical Sciences,Sichuan Provincial People's Hospital,Chengdu,Sichuan,China 610072;Department of Pharmacy,Ziyang People's Hospital,Ziyang,Sichuan,China 641300;School of Medicine,University of Electronic Science and Technology of China,Chengdu,Sichuan,China 610054;Beijing University of Chinese Medicine,Beijing,China 100105;Department of Pharmacy,Gansu Provincial Hospital,Lanzhou,Gansu,China 730000) |
| |
| Abstract: | Objective To investigate the potential adverse drug reactions(ADRs)in the patients with coronavirus disease 2019(COVID-19)treated with combined medication,and to ensure the safety of medication.Methods According to the drug information from drug instruction,Drug Assistant of Dingxiangyuan,New Pharmacology,CNKI,VIP,Wanfang database,Micromedex and UpToDate clinical consultant,combined with clinical pharmaceutical practice experience,the possible interactions and ADRs of the combined medication were analyzed,as well as the key points of pharmaceutical care.Results There were some interactions with each other in the 36 drugs commonly used for treating the COVID-19 in Wuhan fangcang hospitals and designated hospitals,which showed the possibility of potential ADRs.There were contraindications and precautions in traditional Chinese medicine(TCM)injection and TCM decoction.When the patients were given the combination of Chinese and Western medicine,pharmaceutical care should be strengthened.Conclusion There are many potential ADRs in the patients with COVID-19 treated with combined medication,when the patients were given the combination of Chinese and Western medicine,the drug interaction should be evaluated as a whole,the treatment plan should be adjusted individual-ly,and the pharmaceutical care should be strengthened. |
| |
| Keywords: | coronavirus disease 2019 rational drug use adverse drug reactions drug interactions pharmaceutical care |
| 本文献已被 维普 等数据库收录！ |
|
